Free Trial

Hims & Hers Health (HIMS) Stock Price, News & Analysis

Hims & Hers Health logo
$27.49 -0.02 (-0.07%)
Closing price 03:58 PM Eastern
Extended Trading
$26.80 -0.69 (-2.51%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Hims & Hers Health Stock (NYSE:HIMS)

Advanced

Key Stats

Today's Range
$25.71
$28.04
50-Day Range
$18.73
$31.01
52-Week Range
$13.74
$70.43
Volume
13.70 million shs
Average Volume
22.71 million shs
Market Capitalization
$6.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.70
Consensus Rating
Hold

Company Overview

Hims & Hers Health Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

HIMS MarketRank™: 

Hims & Hers Health scored higher than 58% of companies evaluated by MarketBeat, and ranked 458th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hims & Hers Health has received a consensus rating of Hold. The company's average rating score is 2.12, and is based on no strong buy ratings, 4 buy ratings, 11 hold ratings, and 2 sell ratings.

  • Upside/Downside

    The consensus price target for Hims & Hers Health is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Hims & Hers Health has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Hims & Hers Health's stock forecast and price target.
  • Earnings Growth

    Earnings for Hims & Hers Health are expected to grow by 1,125.00% in the coming year, from $0.04 to $0.49 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Hims & Hers Health is -305.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Hims & Hers Health is -305.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Hims & Hers Health has a PEG Ratio of 53.38. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Hims & Hers Health has a P/B Ratio of 11.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Hims & Hers Health's valuation and earnings.
  • Percentage of Shares Shorted

    31.51% of the float of Hims & Hers Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Hims & Hers Health has a short interest ratio ("days to cover") of 2.45, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hims & Hers Health has recently increased by 0.34%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Hims & Hers Health does not currently pay a dividend.

  • Dividend Growth

    Hims & Hers Health does not have a long track record of dividend growth.

  • News Sentiment

    Hims & Hers Health has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 23 news articles for Hims & Hers Health this week, compared to 12 articles on an average week.
  • Search Interest

    166 people have searched for HIMS on MarketBeat in the last 30 days. This is an increase of 1% compared to the previous 30 days.
  • MarketBeat Follows

    48 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 118% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Hims & Hers Health insiders have sold 366.74% more of their company's stock than they have bought. Specifically, they have bought $1,172,732.00 in company stock and sold $5,473,644.00 in company stock.

  • Percentage Held by Insiders

    11.76% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Hims & Hers Health's insider trading history.
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HIMS Stock News Headlines

Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.tc pixel
Hims & Hers Expands With Eucalyptus Acquisition
Three desktop monitors on an office desk display telehealth video consultations between medical professionals and patients.
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?
Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.
Hims & Hers logo overlaid on medical syringes, measuring tape, and financial charts symbolizing telehealth weight-loss market growth.
The Silver Lining of Last Week's Hims & Hers Earnings Miss
Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.
See More Headlines

HIMS Stock Analysis - Frequently Asked Questions

Hims & Hers Health's stock was trading at $32.45 at the beginning of 2026. Since then, HIMS stock has decreased by 15.3% and is now trading at $27.4910.

Hims & Hers Health, Inc. (NYSE:HIMS) posted its earnings results on Monday, May, 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by $0.44. Hims & Hers Health's quarterly revenue was up 3.8% compared to the same quarter last year.
Read the conference call transcript
.

Hims & Hers Health's board approved a share repurchase plan on Monday, November 17th 2025, which permits the company to repurchase $250,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 3% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board of directors believes its stock is undervalued.

Top institutional investors of Hims & Hers Health include Bank of America Corp DE (1.91%), State of Michigan Retirement System (1.03%), Renaissance Technologies LLC (0.93%) and Bank of New York Mellon Corp (0.59%). Insiders that own company stock include Melissa Baird, Michael Chi, Soleil Boughton, Oluyemi Okupe, David B Wells, Patrick Harrison Carroll, Christopher D Payne, Andrew Dudum, Garcia Andrea G Perez, Christiane Pendarvis, Irene Becklund, Irene Becklund, Deborah M Autor, Anja Manuel and Lynne Chou O'keefe.
View institutional ownership trends
.

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/11/2026
Today
6/03/2026
AGM 2026
6/11/2026
Next Earnings (Estimated)
8/10/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Healthcare
Current Symbol
NYSE:HIMS
CIK
1773751
Fax
N/A
Employees
2,442
Year Founded
2017

Price Target and Rating

High Price Target
$60.00
Low Price Target
$21.00
Potential Upside/Downside
+4.4%
Consensus Rating
Hold
Rating Score (0-4)
2.12
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
687.28
P/E Growth
53.38
Net Income
$128.37 million
Net Margins
-0.56%
Pretax Margin
-1.61%
Return on Equity
6.10%
Return on Assets
1.52%

Debt

Debt-to-Equity Ratio
2.18
Current Ratio
1.69
Quick Ratio
1.56

Sales & Book Value

Annual Sales
$2.35 billion
Price / Sales
2.71
Cash Flow
$0.84 per share
Price / Cash Flow
32.87
Book Value
$2.38 per share
Price / Book
11.55

Miscellaneous

Outstanding Shares
231,460,000
Free Float
204,239,000
Market Cap
$6.36 billion
Optionable
Optionable
Beta
2.37

Social Links

Don't wait for the SpaceX IPO Cover

The space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NYSE:HIMS) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners